Literature DB >> 7401236

Nodal involvement as a prognostic indicator in patients with prostatic carcinoma.

G R Prout, J A Heaney, P P Griffin, J J Daly, W U Shipley.   

Abstract

Between 1969 and 1976, 92 patients with proved prostatic carcinoma in stages T0 and T4 underwent pelvic lymphadenectomy. Median followup has been 43 months. All patients had normal serum acid phosphatase levels and no clinical evidence of metastases as determined by physical examination, bone scans and metastatic bone surveys. Pelvic lymph node metastases were noted in 32 cases. Radical prostatectomy was done in 34 cases and 45 patients received radiotherapy, 11 of whom had 125iodine seeds implanted. Progression of the neoplastic process, almost exclusively in the form of bony metastases, occurred in 18 of the 32 patients who had positive pelvic nodes and in 6 of the 60 patients with negative nodes (p less than 0.001). Patients with poorly differentiated carcinoma were more likely to have progression of the disease than those with moderately differentiated carcinoma (p less than 0.01) and no patient with a well differentiated carcinoma had disease progression.

Entities:  

Mesh:

Year:  1980        PMID: 7401236     DOI: 10.1016/s0022-5347(17)55382-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Urology-important advances in clinical medicine: computerized tomography, lymphangiography and Gleason scores for staging prostatic adenocarcinoma.

Authors:  R R Torrey; M Janseen; V Ching
Journal:  West J Med       Date:  1983-04

2.  Assessment of the regional lymph node status in radiation monotherapy of prostatic cancer.

Authors:  L U Kelly; P Moravek; J Schubert; J Wehnert
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

3.  The metastatic potential of prostate carcinomas composed entirely of single malignant glands.

Authors:  P N Brawn; C F Johnson
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

4.  Prostate Cancer Old Problems and New Approaches. Part III. Prevention and Treatment.

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; J.Edson Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

Review 5.  Coumarin (1,2-benzopyrone) for the treatment of prostatic carcinoma.

Authors:  J L Mohler; B T Williams; I M Thompson; M E Marshall
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  [The conformal radiotherapy of localized prostatic carcinoma: acute tolerance and early efficacy].

Authors:  D Zierhut; M Flentje; G Sroka-Perez; V Rudat; R Engenhart-Cabillic; M Wannenmacher
Journal:  Strahlenther Onkol       Date:  1997-02       Impact factor: 4.033

7.  The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.

Authors:  Przemyslaw Waliszewski
Journal:  Front Physiol       Date:  2016-02-11       Impact factor: 4.566

8.  Node dissection in prostate cancer: no answers for old questions.

Authors:  Rodolfo Borges Dos Reis; Antônio Antunes Rodrigues; Rafael Neuppmann Feres; Marcelo Cartapatti da Silva; Valdair Francisco Muglia
Journal:  Int Braz J Urol       Date:  2022 Jan-Feb       Impact factor: 1.541

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.